Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Potenza, L
Right arrow Articles by Torelli, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potenza, L
Right arrow Articles by Torelli, G
Haematologica, Vol 90, Issue 9, 1275-1277
Copyright © 2005 by Ferrata Storti Foundation

Comparative Study

Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission

L Potenza, M Luppi, G Riva, R Marasca, S Martinelli, and G Torelli

Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first complete remission received maintenance therapy with imatinib alone. Two-year progression-free survival was 75%. Quantitative polymerase-chain-reaction (qPCR) monitoring of BCR-ABL showed that: (i) persisting molecular complete response (CR) was associated with long-lasting CR; (ii) molecular relapse did not invariably mean hematologic relapse; (iii) only the wide and rapid increment of BCR-ABL values was predictive of leukemia relapse.


This article has been cited by other articles:


Home page
 Am Soc Clin Oncol Ed BookHome page
M. Wetzler
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: On Target to Improve Outcome
ASCO Educational Book, January 1, 2008; 2008(1): 275 - 279.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.